MolNFT v1 · #73939 · protein
Catalytic domain of stromelysin-1 in complex with N-hydroxy-2-(4- METHYLPHENYLSULFONAMIDO)ACETAMIDE
3OHO: “Catalytic domain of stromelysin-1 in complex with N-hydroxy-2-(4- METHYLPHENYLSULFONAMIDO)ACETAMIDE”. X-ray diffraction, 4 ligands (Z79, CA, ZN), 1 pocket (best druggability 0.53). MolNFT v1 #73939 on GenesisL1: 3D structure…
- PDB
- 3OHO
- Type
- protein
- Length
- 159 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Stromelysin-1
- EC
- 3.4.24.17
- UniProt
- P08254
- Ligands
- Z79, CA, ZN, SO4
- Pockets
- 1 · best druggability 0.53
Structure
x-ray diffraction · 1 distinct chain · 23% helix, 19% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Stromelysin-1 (EC 3.4.24.17) | protein | 159 | 23% helix, 19% strand | P08254 |
Ligands and binding sites
- Z79 · N-hydroxy-N~2~-[(4-methoxyphenyl)sulfonyl]glycinamide · ligand · chains A
- CA · Calcium ion · metal · 3 copies · chains A
- ZN · Zinc ion · metal · 2 copies · chains A
- SO4 · Sulfate ion · ion · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 182 | 0.53 | 0.79 | 28 | ZN, Z79 |
Compared structures
- 3OHO · catalytic domain of stromelysin-1 in complex with… · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P08254
- Elsewhere: RCSB PDB 3OHO · PDBe 3OHO · UniProt P08254
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.